{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:59:38Z","timestamp":1782449978956,"version":"3.54.5"},"reference-count":55,"publisher":"Informa UK Limited","issue":"11","funder":[{"name":"not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2020,11,1]]},"DOI":"10.1080\/14712598.2020.1830056","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T14:40:55Z","timestamp":1601649655000},"page":"1275-1282","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":20,"title":["Pembrolizumab for the treatment of Hodgkin Lymphoma"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-8042","authenticated-orcid":false,"given":"Samer A.","family":"Al Hadidi","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX, USA"},{"name":"Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun Ju","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"cit0002","volume-title":"Classification of tumours of haematopoietic and lymphoid tissues","author":"WHO","year":"2017"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930315)71:6<2062::AID-CNCR2820710622>3.0.CO;2-0"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8401"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21716"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21438"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0385-y"},{"key":"cit0009","unstructured":"American Cancer Society. Cancer facts & figures 2019. 2019."},{"key":"cit0010","unstructured":"Adcetris (brentuximab vedotin) [prescribing information]. Bothell, WA: Seattle Genetics; [Cited 2020 May 6]. https:\/\/seagendocs.com\/Adcetris_Full_Ltr_Master.pdf"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"cit0012","first-page":"2277","volume":"9","author":"Chen R","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.332"},{"key":"cit0014","unstructured":"Bristol-Myers Squibb: Opdivo (nivolumab) Highlights of prescribing information. cited 2020 May 6]. http:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf"},{"key":"cit0015","unstructured":"KEYTRUDA\u00ae (pembrolizumab) for injection, for intravenous use. cited 2020 May 6]. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00829"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02965"},{"key":"cit0018","author":"Shaywitz D","year":"2017","journal-title":"Forbes"},{"key":"cit0019","doi-asserted-by":"crossref","unstructured":"2019 Merck Annual Report & 2020 Proxy. [cited 2020 May 18]. https:\/\/s21.q4cdn.com\/488056881\/files\/doc_financials\/2019\/q4\/2019-Form-10-K-Final.pdf","DOI":"10.1016\/S1353-4858(20)30039-8"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2607"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1216976"},{"key":"cit0022","unstructured":"Pharmacology Review(s) U.S. Food and Drug Administration; Silver Spring, MD. [cited 2020 May 9]. Center for Drug Evaluation and Research, Application Number: 125514Orig1s000. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125514Orig1s000PharmR.pdf"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12132"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9528-y"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00748-2"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001367"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000324"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127280"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1702178"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1602262"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8005"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.9046"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.6025"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123163"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000215"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123906"},{"key":"cit0039","unstructured":"National Comprehensive Cancer Network. Management of Immunotherapy-Related Toxicities (Version 1.2020). [cited 2020 May 8]. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf."},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0538"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761346"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13186"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00792-7"},{"key":"cit0045","first-page":"1","author":"Large S","year":"201","journal-title":"J Med Econ"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01342"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0167"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14369"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.77"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013804"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01437"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-24"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1654100"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0363-1"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0755"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2020.1830056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T01:53:33Z","timestamp":1620438813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2020.1830056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11,1]]}},"alternative-id":["10.1080\/14712598.2020.1830056"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2020.1830056","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}